Severe Vincristine-Induced Peripheral Neuropathic Weakness in Both Lower Limbs in an Asian Adolescent with CYP3A4 rs2740574 TT Genotype
DOI: https://doi.org/10.2147/pgpm.s460878
2024-04-17
Pharmacogenomics and Personalized Medicine
Abstract:Dongdong Zhang, 1 Jie Bai 2 1 Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, People's Republic of China; 2 Department of Neurology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, People's Republic of China Correspondence: Dongdong Zhang, Department of Oncology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Jiefang Road No. 15, Xiangyang, Hubei, 441000, People's Republic of China, Tel +8615072278600, Email Background: Vincristine (VCR)-induced peripheral neuropathy (VIPN) is a common adverse reaction during cancer treatment, typically characterized by numbness and paresthesias. This study aimed to report a rare case of VIPN with an atypical genotype, manifesting as grade 3 weakness of the lower limbs. Case Presentation: A 19-year-old man, diagnosed with alveolar rhabdomyosarcoma for 8 months, was transferred to our hospital for further treatment after the failure of first-line treatment. He developed severe long-standing weakness in both lower limbs and could not walk after four sessions of second-line chemotherapy. The diagnosis of VIPN was confirmed based on the patient's physical examination, imaging studies, electromyogram results, and treatment history. Furthermore, the pharmacogenetic analysis indicated that the patient harbored CYP3A4 rs2740574 TT genotypes. Conclusion: We have reported for the first time a VIPN patient whose main clinical manifestation is severe weakness in both lower limbs, accompanied by the CYP3A4 rs2740574 TT phenotype. This case may provide new information on the phenotypic features of VIPN, and may help to better understand the disease pathogenesis and contributing factors. Keywords: vincristine, vincristine-induced peripheral neuropathy, CYP3A rs2740574 TT genotype Vinca alkaloids (VAs) are the earliest and classic microtubule-targeting agents that can interfere with continuous mitotic division and disrupt cancer cell growth. 1 VCR is one of the most important VAs incorporated into several polychemotherapy regimens for the treatment of hematological malignancies, lymphoma, sarcomas and pediatric cancers. However, the dose-limiting side effects caused by VCR can potentially lead to treatment discontinuations and interruptions, and even impact the patients' quality of life. VIPN is the most common adverse reaction in clinical practice. As VCR can poorly penetrate across the blood–brain barrier, the occurrence of central nervous system toxicity is relatively low. The VIPN etiology is mainly associated with the disruption of microtubule structures, axonal dysfunction, and inflammation. 2 VIPN can be categorized into sensory neuropathy, autonomic neuropathy, and motor neuropathy based on clinical symptoms. 2 Sensory neuropathy is more common, with paresthesia, numbness, neuropathic pain or jaw pain, and sensory abnormalities as the main clinical manifestations. Autonomic neuropathy can manifest as symptoms such as urinary retention, constipation, and so on. 3 However, manifestations of autonomic neurotoxicity are difficult to identify because symptoms are easily confused with other treatment-related side effects. Motor neuropathy can be presented as extremity weakness, walking difficulties, and impaired balance, and its incidence is relatively high in pediatric patients with cancer receiving long-time VCR-based treatment. Further, these symptoms usually develop early during treatment and persist for a relatively long time. 4 Currently, the Common Terminology Criteria for Adverse Events and Total Neuropathy Score-Pediatric Vincristine tools are commonly used for evaluating VIPN. 5,6 Previous studies have shown that multiple factors contribute to the development and severity of VIPN, including age, genetic ancestry, dose, impaired liver function, combination medicine and single-nucleotide polymorphisms (SNPs). 7–9 Previous studies indicated that CYP3A4 was not prevalent in Asian. However, CYP3A4 rs2740574 genotype commonly associated with a severe peripheral neurotoxicity associated with taxanes. 10 This study reported a rare case of VIPN presenting as severe weakness in both lower limbs in an Asian adolescent harboring an uncommon CYP3A4 rs2740574 TT genotype. A 19-year-old obese male, complaining of protruding eyeballs, accompanied with decreased and blurred vision for 1 day, was admitted to Guangzhou People's Hospital. Magnetic resonance imaging (MRI) suggested a mass in the left ethmoid sinus and orbit, with compressed left medial rectus muscle, leading to the eyeball protrusion. He then underwent endoscopic excision of the nasal mass. -Abstract Truncated-
pharmacology & pharmacy